FDA Brief

Warning letters Drugs

FDA warning letter to

IDO Pharm Co., Ltd.

High riskIssued May 4Posted May 12Center for Drug Evaluation and Research (CDER)

IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

What happened

FDA inspected the facility from November 10 to 13, 2025. It found no written production and process control procedures; an unvalidated system used to make a drug component with stagnant material in hoses and visible particulate matter floating on the surface, including what appeared to be an insect; no process or cleaning validation for over-the-counter drugs; and unvalidated gas chromatographic methods. FDA also found the quality control unit failed to ensure stability testing, adequate batch records and routine equipment calibration.

What FDA found

  1. The firm lacked written procedures for production and process controls to ensure drug identity, strength, quality and purity.

    21 CFR 211.100(a)
  2. The system used to make a drug component was not validated, and hoses and a tank had stagnant material and visible particulate matter, including what appeared to be an insect.

    21 CFR 211.100(a)
  3. The firm did not perform process validation or equipment cleaning validation for its over-the-counter drug products.

    21 CFR 211.100(a)
  4. The firm used unvalidated gas chromatographic methods for assay and impurity testing and did not test a raw material for impurities.

    21 CFR 211.160(b)
  5. The quality control unit failed to ensure a written stability program to set storage conditions and expiration dates.

    21 CFR 211.22; 21 CFR 211.166(a)
  6. The quality control unit failed to ensure adequate batch production records and routine equipment calibration.

    21 CFR 211.22; 21 CFR 211.188; 21 CFR 211.68(a)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, risk assessments, validation and remediation plans, and retain-sample testing. FDA also recommends a qualified CGMP consultant and says it may withhold approvals and refuse imports until compliance is confirmed.

Who should pay attention

  • brands or distributors that buy finished drugs from this contract manufacturer
  • US importers of Korean OTC drug products
  • companies relying on this firm's CGMP status for applications or supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk